Stereotactic radiotherapy for wet age-related macular degeneration (intrepid): Influence of baseline characteristics on clinical response

Retina

Volumn 35, Issue 2, 2015, Pages 194-204

  Jackson, Timothy L ^a   Shusterman, E Mark ^b   Arnoldussen, Mark ^b   Chell, Erik ^b   Wang, Kun ^c   Moshfeghi, Darius M ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b CymaBay Therapeutics   (United States)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti vascular endothelial growth factor; INTREPID study; neovascular age related macular degeneration; radiation; ranibizumab; stereotactic radiotherapy; wet age related macular degeneration

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OCULAR FIBROSIS; OPTICAL COHERENCE TOMOGRAPHY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINAL THICKNESS; RETREATMENT; STEREOTACTIC RADIOTHERAPY; STEREOTACTIC TREATMENT; THERAPY EFFECT; TREATMENT RESPONSE; VISUAL ACUITY; WET MACULAR DEGENERATION; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RADIOSURGERY; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RADIOSURGERY; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84922398127     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000283     Document Type: Article

References (25)

1. Chakravarthy U, Houston RF, Archer DB. Treatment of agerelated subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol 1993;77:265-273.
2. Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, et al. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes. Am J Ophthalmol 2013;155:1000-1008.e2.
3. Moshfeghi AA, Morales-Canton V, Quiroz-Mercado H, et al. 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a "radiation-first" strategy. Br J Ophthalmol 2012;96:1320-1324.
4. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 24-Gy low-voltage X-Ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging 2012;43:20-24.
5. Moshfeghi AA, Canton VM, Quiroz-Mercado H, et al. 16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy. Ophthalmic Surg Lasers Imaging 2011;42:460-467.
6. Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology 2013;120:1893-900.
7. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1.
8. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-671.
9. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in agerelated macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119:992-1000.
10. Petrarca R, Richardson M, Douiri A, et al. Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12-month results. Retina 2013;33: 1232-1240.
11. Petrarca R, Jackson TL. Radiation therapy for neovascular agerelated macular degeneration. Clin Ophthalmol 2011;5:57-63.
12. Chakravarthy U, Klein SB. Radiobiology of CNV of AMD. In: Alberti WE, Richard G, Sagerman RH, eds. Age-Related Macular Degeneration: Current Treatment Concepts. Vol 9 Berlin, Germany: Springer-Verlag; 2000.
13. Chakravarthy U, Gardiner TA, Archer DB, Maguire CJ. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Curr Eye Res 1989;8:337-348.
14. Mallinckrod CH, Lane PW, Schnell D, et al. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Info J 2008;42:303-319.
15. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012;96:752-756.
16. Petrarca R, Dugel PU, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology 2013;120:328-333.
17. Petrarca R, Dugel PU, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina 2014;34:874-879.
18. Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology 2012;119:1425-1431.
19. Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013; 120:317-327.
20. Jackson TL, Dugel PU, Bebchuk JD, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology 2013;120:1597-1603.
21. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
22. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119: 1388-1398.
23. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
24. Krebs I, Hagen S, Smretschnig E, et al. Reproducibility of segmentation error correction in age-related macular degeneration: stratus versus cirrus OCT. Br J Ophthalmol 2012;96:271-275.
25. Patel PJ, Chen FK, da Cruz L, Tufail A. Segmentation error in stratus optical coherence tomography for neovascular agerelated macular degeneration. Invest Ophthalmol Vis Sci 2009;50:399-404.